Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

NCT02449681 is registered in ClinicalTrials.gov with Rain Oncology Inc as lead sponsor.

NCT NCT02449681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02449681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
Lead sponsor
Rain Oncology Inc
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2015
Completion date
January 31, 2017
Enrollment
30 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic head-and-neck squamous-cell carcinoma